Home › Diffuse Large B-Cell Lymphoma
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma na nagre-recruit sa U.S.
105 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- New York City, NY20 pag-aaral
- Baldwin Park, CA19 pag-aaral
- Los Angeles, CA18 pag-aaral
- Houston, TX18 pag-aaral
- Chicago, IL18 pag-aaral
- Milwaukee, WI17 pag-aaral
- Nashville, TN17 pag-aaral
- Boston, MA17 pag-aaral
- Philadelphia, PA15 pag-aaral
- Durham, NC15 pag-aaral
- Portland, OR15 pag-aaral
- Cleveland, OH13 pag-aaral
- Seattle, WA13 pag-aaral
- Dallas, TX13 pag-aaral
- Washington, DC13 pag-aaral
- Salt Lake City, UT12 pag-aaral
- Richmond, VA11 pag-aaral
- Denver, CO11 pag-aaral
- Cincinnati, OH11 pag-aaral
- Rochester, MN10 pag-aaral
- Columbus, OH10 pag-aaral
- Atlanta, GA10 pag-aaral
- Jacksonville, FL9 pag-aaral
- Omaha, NE9 pag-aaral
- Louisville, KY9 pag-aaral
- Cedar Rapids, IA9 pag-aaral
- Grand Rapids, MI8 pag-aaral
- Edison, NJ8 pag-aaral
- St. Louis, MO8 pag-aaral
- San Antonio, TX8 pag-aaral
- San Francisco, CA8 pag-aaral
- New Haven, CT8 pag-aaral
- Miami, FL8 pag-aaral
- Indianapolis, IN7 pag-aaral
- Charlottesville, VA7 pag-aaral
- Aurora, CO7 pag-aaral
- Kansas City, MO7 pag-aaral
- Sacramento, CA6 pag-aaral
- Baltimore, MD6 pag-aaral
- Detroit, MI6 pag-aaral
Ayos sa estado
- Alabama4 pag-aaral
- Arizona13 pag-aaral
- Arkansas4 pag-aaral
- California43 pag-aaral
- Colorado19 pag-aaral
- Connecticut8 pag-aaral
- District of Columbia4 pag-aaral
- Florida25 pag-aaral
- Georgia15 pag-aaral
- Idaho4 pag-aaral
- Illinois22 pag-aaral
- Indiana9 pag-aaral
- Iowa11 pag-aaral
- Kansas6 pag-aaral
- Kentucky12 pag-aaral
- Louisiana7 pag-aaral
- Maryland15 pag-aaral
- Massachusetts17 pag-aaral
- Michigan17 pag-aaral
- Minnesota15 pag-aaral
- Missouri8 pag-aaral
- Montana3 pag-aaral
- Nebraska9 pag-aaral
- Nevada3 pag-aaral
- New Jersey14 pag-aaral
- New Mexico3 pag-aaral
- New York29 pag-aaral
- North Carolina20 pag-aaral
- North Dakota4 pag-aaral
- Ohio25 pag-aaral
- Oklahoma5 pag-aaral
- Oregon15 pag-aaral
- Pennsylvania19 pag-aaral
- South Carolina4 pag-aaral
- South Dakota3 pag-aaral
- Tennessee20 pag-aaral
- Texas31 pag-aaral
- Utah14 pag-aaral
- Virginia17 pag-aaral
- Washington18 pag-aaral
- Wisconsin20 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07519772A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06890884Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT03223610Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT05272384Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT06806033A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07735533Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT04002947Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06649812Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT05852717AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07649304A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07101328A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07188558Auto Stem Cell Transplant for Lymphoma Patients
Nagre-recruitPhase 2
Hanggang edad 75 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT03125642A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07226843A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05139017Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Nagre-recruitObservasyonal na pag-aaral
Edad 10 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06323447A Study of ARC-02 in B-cell NHL
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07691606A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 2
Edad 65 hanggang 80 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06765317Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Nagre-recruitPhase 2
Edad 65 hanggang 99 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT05952024Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06500273Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06131801Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT05890352Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.